BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals announced today the successful completion of its first study to assess the tolerability of VGX’s patented CELLECTRA™ electroporation device in humans. Ten healthy adult volunteers were treated with CELLECTRA™ device and were asked to report the level of discomfort they experienced immediately after electroporation and at various times thereafter. The procedure was generally well tolerated. On average, the patients reported a moderate level of discomfort during the procedure. However, the discomfort was short-lived, with comfort levels approaching baseline levels within 30 minutes following the procedure. Other complaints were mild and did not require any treatment.
